+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thrombolytic Drug Market by Drug Class (Streptokinase, Tissue Plasminogen Activator, Urokinase), Indication (Acute Myocardial Infarction, Deep Vein Thrombosis, Ischemic Stroke), Route Administration, End User, Patient Group - Global Forecast 2025-2030- Product Image
Thrombolytic Drug Market by Drug Class (Streptokinase, Tissue Plasminogen Activator, Urokinase), Indication (Acute Myocardial Infarction, Deep Vein Thrombosis, Ischemic Stroke), Route Administration, End User, Patient Group - Global Forecast 2025-2030- Product Image
Sale

Thrombolytic Drug Market by Drug Class (Streptokinase, Tissue Plasminogen Activator, Urokinase), Indication (Acute Myocardial Infarction, Deep Vein Thrombosis, Ischemic Stroke), Route Administration, End User, Patient Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5612901
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The thrombolytic drug market is rapidly transforming, driven by innovation in biotechnology, evolving clinical needs, and changing global healthcare infrastructures. Senior decision-makers must understand the shifting landscape to capture emerging opportunities, ensure regulatory alignment, and optimize their organizations' strategic positioning in a highly competitive sector.

Market Snapshot: Thrombolytic Drug Market Size and Growth

The global thrombolytic drug market grew from USD 1.43 billion in 2024 to USD 1.69 billion in 2025. It is expected to continue expanding at a 17.85% CAGR, reaching USD 3.84 billion by 2030. Significant market momentum is being shaped by the rising global incidence of ischemic stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism. The demand for safer, more targeted, and easier-to-administer medications is increasing. Stakeholders are also seeing the beneficial effects of healthcare infrastructure improvements in high-growth and emerging regions.

Scope & Segmentation in the Thrombolytic Drug Market

  • Drug Classes: Streptokinase, tissue plasminogen activators such as alteplase, reteplase, and tenecteplase, and urokinase, each providing distinct clinical profiles and market relevance.
  • Indications: Acute myocardial infarction, deep vein thrombosis, ischemic stroke, and pulmonary embolism, representing the main drivers for therapeutic adoption and protocol development.
  • Routes of Administration: Intra-arterial and intravenous, addressing needs related to precision targeting and systemic treatment strategies.
  • End Users: Ambulatory centers, emergency medical services, and hospitals, reflecting diverse operational priorities and equipment needs.
  • Patient Groups: Adult and pediatric populations, highlighting the importance of tailored dosing and safety protocols.
  • Geographies: Americas (including key states and countries), Europe, Middle East & Africa (covering both advanced and emerging markets), and Asia-Pacific, where rapid growth and cross-regional collaborations present opportunities and unique challenges.
  • Leading Companies Profiled: F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Sanofi S.A., Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Cipla Limited, Apotex Inc., Cadila Healthcare Limited, and Biocon Limited.

Key Takeaways for Senior Decision-Makers

  • Significant advances in molecular biology and peptide engineering are driving the evolution of next-generation thrombolytic agents, improving specificity and lowering risk profiles for vulnerable patient groups.
  • Biosimilar competition is reshaping market dynamics by pressuring prices and expanding access, making therapy options more viable in price-sensitive regions.
  • Digital health integration, including mobile stroke units and point-of-care diagnostics, is reducing time-to-treatment and influencing product selection decisions globally.
  • Regulatory environments are adapting quickly, facilitating shorter drug development lifecycles and encouraging innovative delivery technologies to reach market faster.
  • Regional variation in reimbursement models and clinical workflows requires market participants to employ highly tailored localization and partnership strategies to gain traction in new and existing markets.
  • Collaboration between large pharmaceutical companies and specialized biotech firms is accelerating product pipelines and dispersing risk, especially in the discovery and early development phases of thrombolytic therapies.

Tariff Impact: Navigating Supply Chain and Pricing Shifts

The introduction of United States tariffs in 2025 has disrupted the thrombolytic drug supply chain by increasing duties on imported active ingredients and delivery systems. This has compelled companies to revisit global sourcing and encourage regional manufacturing initiatives. Cost adjustments are prompting healthcare providers to evaluate alternative agents and partnership models, while organizations respond by supporting local supply must remain agile amid evolving trade policies and complex cross-border access challenges.

Methodology & Data Sources

Our research draws on primary interviews with clinicians, industry leaders, regulatory advisors, and hospital procurement officials across global markets. This is complemented by an extensive review of clinical literature, regulatory filings, and reimbursement guidelines, validated against proprietary databases and further scrutinized by external advisory panels to ensure actionable accuracy.

Why This Report Matters

  • Provides senior executives with strategic, evidence-based insights on technological advancements, clinical workflow trends, and competitive positioning.
  • Enables industry stakeholders to anticipate regulatory and market access shifts, ensuring optimal pipeline prioritization and resource allocation.
  • Equips organizations with targeted intelligence on regional dynamics and emerging partner ecosystems, supporting business development and expansion strategies.

Conclusion

This report equips decision-makers with a comprehensive understanding of the thrombolytic drug market’s opportunities and challenges. Stakeholders can act with confidence by leveraging actionable insights tailored to clinical, technological, and regional developments.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of biosimilar tissue plasminogen activator formulations disrupting pricing and access in developed markets
5.2. Adoption of AI driven imaging analysis platforms to refine patient selection for thrombolytic interventions in acute stroke
5.3. Development of ultrasound enhanced thrombolysis techniques to improve clot dissolution rates and patient outcomes
5.4. Integration of telemedicine enabled stroke assessment protocols to reduce door to needle times in rural healthcare settings
5.5. Advancements in microbubble mediated targeted delivery systems enhancing efficacy of thrombolytic drugs for ischemic stroke
5.6. Regulatory shifts encouraging real world evidence generation to demonstrate cost effectiveness of novel thrombolytic therapies
5.7. Rising focus on combination therapies pairing thrombolytics with neuroprotective agents to expand treatment windows and efficacy
5.8. Market expansion driven by growing stroke incidence in emerging economies and improved healthcare infrastructure investments
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Thrombolytic Drug Market, by Drug Class
8.1. Introduction
8.2. Streptokinase
8.3. Tissue Plasminogen Activator
8.3.1. Alteplase
8.3.2. Reteplase
8.3.3. Tenecteplase
8.4. Urokinase
9. Thrombolytic Drug Market, by Indication
9.1. Introduction
9.2. Acute Myocardial Infarction
9.3. Deep Vein Thrombosis
9.4. Ischemic Stroke
9.5. Pulmonary Embolism
10. Thrombolytic Drug Market, by Route Administration
10.1. Introduction
10.2. Intra Arterial
10.3. Intravenous
11. Thrombolytic Drug Market, by End User
11.1. Introduction
11.2. Ambulatory Center
11.3. Emergency Medical Service
11.4. Hospital
12. Thrombolytic Drug Market, by Patient Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Americas Thrombolytic Drug Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Thrombolytic Drug Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Thrombolytic Drug Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche AG
16.3.2. Boehringer Ingelheim International GmbH
16.3.3. Sanofi S.A.
16.3.4. Teva Pharmaceutical Industries Limited
16.3.5. Sandoz International GmbH
16.3.6. Sun Pharmaceutical Industries Limited
16.3.7. Cipla Limited
16.3.8. Apotex Inc.
16.3.9. Cadila Healthcare Limited
16.3.10. Biocon Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THROMBOLYTIC DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. THROMBOLYTIC DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. THROMBOLYTIC DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. THROMBOLYTIC DRUG MARKET: RESEARCHAI
FIGURE 26. THROMBOLYTIC DRUG MARKET: RESEARCHSTATISTICS
FIGURE 27. THROMBOLYTIC DRUG MARKET: RESEARCHCONTACTS
FIGURE 28. THROMBOLYTIC DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. THROMBOLYTIC DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY STREPTOKINASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY STREPTOKINASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ALTEPLASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ALTEPLASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RETEPLASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RETEPLASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TENECTEPLASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TENECTEPLASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY UROKINASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY UROKINASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRA ARTERIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRA ARTERIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY AMBULATORY CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY AMBULATORY CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY EMERGENCY MEDICAL SERVICE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY EMERGENCY MEDICAL SERVICE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 83. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 84. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 85. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 86. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 87. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 94. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 95. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 96. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 97. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 98. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 99. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 106. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 157. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 158. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 159. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 160. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 161. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 168. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 169. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 172. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 173. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 180. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 193. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 194. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 195. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 196. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 197. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 204. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 205. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 206. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 207. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 208. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 209. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 216. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 253. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 256. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 257. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 264. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 277. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 278. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 279. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 280. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 281. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 288. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 289. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 290. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 291. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 292. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 293. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 300. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 301. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 302. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 313. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 314. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 316. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 325. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 326. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 327. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 328. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 329. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 332. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 333. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 334. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 335. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 336. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 337. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 338. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 339. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2024 (USD MILLION)
TABLE 340. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2025-2030 (USD MILLION)
TABLE 341. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 342. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABL

Samples

Loading
LOADING...

Companies Mentioned

  • F. Hoffmann-La Roche AG
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Apotex Inc.
  • Cadila Healthcare Limited
  • Biocon Limited

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.69 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.84 Billion
Compound Annual Growth Rate17.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Peripheral Arterial Disease Therapeutics Market by Product Type (Anticoagulants, Antiplatelet Agents, Thrombolytics), Indication (Critical Limb Ischemia, Intermittent Claudication), End User, Route Of Administration - Global Forecast 2025-2030 - Product Image

Peripheral Arterial Disease Therapeutics Market by Product Type (Anticoagulants, Antiplatelet Agents, Thrombolytics), Indication (Critical Limb Ischemia, Intermittent Claudication), End User, Route Of Administration - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Thrombolytic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Thrombolytic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 130 Pages
  • Global
From
Urokinase Market by Product Type (Human Urokinase, Recombinant Urokinase), Form (Liquid Solution, Powder), Application, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Urokinase Market by Product Type (Human Urokinase, Recombinant Urokinase), Form (Liquid Solution, Powder), Application, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Acute Ischemic Stroke Drugs: Market Share, and Growth Analysis by Product Type (Thrombolytics, Antiplatelet Agents, Anticoagulants), Application, End User, Technology - Product Image

Acute Ischemic Stroke Drugs: Market Share, and Growth Analysis by Product Type (Thrombolytics, Antiplatelet Agents, Anticoagulants), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Urokinase - Global Strategic Business Report - Product Image

Urokinase - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From

About the Thrombolytics Market

Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen. The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.